activating the Immune response In ovarian cancer study

Recruiting

• Conditions: ovarian carcinoma; malignant ovarian tumors; 10027656

• Registration Number: NL-OMON56684
• Lead Sponsor: Catharina-ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 9 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 90

Inclusion Criteria

-Subjects should be at least 18 years old and mentally competent
-Newly diagnosed patients with ovarian carcinoma (OC) who go for primary
debulking surgery or patients with OC are scheduled for interval debulking
- Controls: women who undergo surgery for benign gynaecological conditions
under general anaesthesia

Exclusion Criteria

-Mentally incompetent
-Pregnant or breastfeeding
-Known inflammatory or infectious diseases or an immunosuppressive status
-Using medication interfering with the immune system
-Severe comorbidities: other active malignancy (except for basal cell carcinoma
and other in situ carcinomas)
-Serious psychiatric pathology
-A self-reported alcohol consumption of >21 units per week
-Bleedings disorder
-History of splenectomy
-Not mastering the Dutch language

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Characterizing the immune status of ovarian carcinoma patients compared to<br /><br>cancer-free controls, with a focus on hematopoietic organs and the immune cells<br /><br>originating from them. This will be accomplished by assessing the<br /><br>transcriptional, epigenetic, and functional programming of circulating<br /><br>monocytes and myeloid precursor cells in OC.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>none</p><br>